Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System

SARS-CoV-2 is an appropriate name for the new coronavirus

(2020) Yuntao Wu et al.   LANCET

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

(2020) Qihui Wang et al.   CELL

SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship

(2020) Volodymyr V. Oberemok et al.   INFLAMMATION RESEARCH

Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes

(2020) Grace L. Chen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comorbidities and multi-organ injuries in the treatment of COVID-19

(2020) Tianbing Wang et al.   LANCET

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

(2020) Xiuyuan Ou et al.   Nature Communications

SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far

(2020) Firas A. Rabi et al.   Pathogens

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

(2020) Mark P. Lythgoe et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Tauroursodeoxycholic acid (TUDCA) inhibits influenza A viral infection by disrupting viral proton channel M2

(2018) Ning Li et al.   Science Bulletin

Major findings and recent advances in virus–like particle (VLP)-based vaccines

(2017) Mona O. Mohsen et al.   SEMINARS IN IMMUNOLOGY

Escherichia coli-derived virus-like particles in vaccine development

(2017) Xiaofen Huang et al.   npj Vaccines

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers

(2014) Jenny G.H. Low et al.   VACCINE

Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles

(2012) Qinjian Zhao et al.   Nanomedicine-Nanotechnology Biology and Medicine

Virus-like particle (VLP)-based vaccines for pandemic influenza

(2012) Constantino López-Macías   Human Vaccines & Immunotherapeutics

Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice

(2010) Chuan Li et al.   VACCINE